Statement Of Financial Position [Abstract]

ABIONYX Pharma - Filing #2821124

Concept	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-01-01	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01
Statement of financial position [abstract]
Assets [abstract]
Property, plant and equipment	—	—	—	—	—	—	91,000 EUR	—	—	—	—	—	10,000 EUR	—	—	—	—	—	—	—	—	—
Right-of-use assets	—	—	—	—	—	—	24,000 EUR	—	—	—	—	—	83,000 EUR	—	—	—	—	—	—	—	—	—
Deferred tax assets	—	—	—	—	—	—	0 EUR	—	—	—	—	—	0 EUR	—	—	—	—	—	—	—	—	—
Cash and cash equivalents	—	—	—	—	—	—	9 154 EUR	8 331 EUR	—	—	—	—	8 331 EUR	—	—	—	—	—	—	—	11 457 EUR	—
Assets	—	—	—	—	—	—	10 288 EUR	—	—	—	—	—	10 249 EUR	—	—	—	—	—	—	—	—	—
Equity and liabilities [abstract]
Equity [abstract]
Issued capital	—	—	—	—	—	—	1 232 EUR	—	—	—	—	—	1 097 EUR	—	—	—	—	—	—	—	—	—
Share premium	—	—	—	—	—	—	170 322 EUR	—	—	—	—	—	168 619 EUR	—	—	—	—	—	—	—	—	—
Equity	176 730 EUR	1 232 EUR	30,000 EUR	39,000 EUR	11 797 EUR	170 322 EUR	6 629 EUR	—	11 699 EUR	25,000 EUR	92,000 EUR	168 621 EUR	6 666 EUR	174 818 EUR	1 097 EUR	11 601 EUR	25,000 EUR	947,000 EUR	167 832 EUR	176 595 EUR	3 838 EUR	78,000 EUR
Liabilities [abstract]
Deferred tax liabilities	—	—	—	—	—	—	0 EUR	—	—	—	—	—	0 EUR	—	—	—	—	—	—	—	—	—
Equity and liabilities	—	—	—	—	—	—	10 288 EUR	—	—	—	—	—	10 249 EUR	—	—	—	—	—	—	—	—	—